News – Page 34 – Alligator Bioscience

2017-05-04

Regulatory

Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today presented new pre-clinical data on the CD40 agonistic immuno-oncology ...

2017-05-02

Today, on May 2, 2017, an annual shareholders’ meeting was held in Alligator Bioscience AB. A summary of the resolutions adopted follows bel ...

2017-05-02

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017. “In the first quarte ...

2017-04-28

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will present new pre-clinical data on the CD40 agon ...

2017-03-31

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the number of shares and votes in Alligator Bios ...

2017-03-23

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the first phase I study with ADC-1013, a human, ...

2017-03-222022-09-20

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announces that that the Swedish version of Annual Report for 20 ...

2017-03-22

The shareholders of Alligator Bioscience AB, Reg. No 556597-8201, are hereby invited to attend the annual shareholders’ meeting to be held o ...

2017-02-17

Regulatory

Summary During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this were new shares ...